Earlier immunochemotherapy may boost survival in small cell lung cancer

A study of 397 patients with extensive-stage small cell lung cancer (ES-SLC) found that receiving immunochemotherapy (atezolizumab or durvalumab plus chemotherapy) before 3:00 pm was associated with significantly better outcomes: a 52% lower risk of progression and 63% lower risk of death compared with later administration.

Clinical takeaway: When scheduling immunochemotherapy for ES-SCLC, consider morning or early afternoon infusions to optimize outcomes.

Source:

Huang Z, et al. (2025, December 15). Cancer. Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer. https://pubmed.ncbi.nlm.nih.gov/41355404/